Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Predictive Oncology Inc. (NASDAQ:POAI)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $13.82 and traded as low as $9.26. Predictive Oncology shares last traded at $9.42, with a volume of 22,443 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Predictive Oncology in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

Predictive Oncology Trading Up 1.2%

The stock has a 50 day moving average of $13.85 and a 200-day moving average of $13.82. The stock has a market capitalization of $7.19 million, a P/E ratio of -3.09 and a beta of 1.32.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings data on Wednesday, August 13th. The medical instruments supplier reported ($3.30) EPS for the quarter, missing the consensus estimate of ($1.35) by ($1.95). Predictive Oncology had a negative net margin of 587.31% and a negative return on equity of 722.01%. The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $1.50 million. Research analysts anticipate that Predictive Oncology Inc. will post -2.08 EPS for the current year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.